Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research
This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
The DROPZYLLA® platform was used in early 2020 to rapidly generate SARS-CoV-2-specific antibodies from convalescent COVID-19 donors, yielding neutralizing antibodies within 3-6 weeks. One antibody, MTX-COVAB, showed strong efficacy against all known variants at that time and went into clinical development.
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
BKV-nephropathy remains a major cause of premature kidney allograft failure, necessitating proactive screening, monitoring, and timely immunosuppression reduction. The updated Second International Consensus Guidelines review significant advances and provide updated recommendations, emphasizing the need for further research and randomized clinical trials.
Antibody repertories of tumor-infiltrating B cells
This poster, presented 2023 at CICON, details the diverse antibody repertoires of tumor-infiltrating B cells, highlighting their potential for anti-tumor activity and the use of the Dropzylla platform for comprehensive analysis and biobanking.
Antibodies against Endogenous Retroviruses Promote Lung Cancer Immunotherapy
Cancer derived antibodies have anti-tumour activity and promote response to lung cancer immunotherapy
Discovery of superior functional antibodies from comprehensive recombinant antibody repertoires
This poster, presented 2022 at PEGS Europe, describes the discovery of superior functional antibodies using Dropzylla, a microfluidic-based single-cell analysis platform, highlighting its comprehensive antibody repertoire coverage and high-throughput screening capabilities for therapeutic applications.
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
In most cancer indications, B cells are associated with a favourable prognostic outcome.
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma
B cells are associated with a favourable cancer prognosis in lung cancer
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Tumour infiltrating B cells secrete antibodies that bind cancer cells and show functional anti-tumour activity in ovarian cancer.
Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research
This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
BKV-nephropathy remains a major cause of premature kidney allograft failure, necessitating proactive screening, monitoring, and timely immunosuppression reduction. The updated Second International Consensus Guidelines review significant advances and provide updated recommendations, emphasizing the need for further research and randomized clinical trials.
Advancing Patient-Centered Research: Enabling the Patient Voice to Be Heard
The article discusses the importance of incorporating the patient voice in patient-centered research, particularly in the context of kidney diseases, to improve healthcare outcomes and ensure that patient perspectives and needs are adequately addressed.
BK Virus Infection and BK-Virus-Associated Nephropathy in Renal Transplant Recipients
BK polyomavirus (BKV) is highly infective, often causing asymptomatic infections in childhood and remaining latent in kidney cells. In renal transplant recipients, BKV can reactivate, leading to nephropathy and significant graft loss, with current treatments focusing on reducing immunosuppression and emphasizing the importance of early diagnosis and surveillance for better outcomes.
The economic burden of kidney graft failure in the United States
The economic burden of kidney graft failure is significant. Reducing graft failure would improve quality of life, extend patient survival, and result in reduced health care spending.
Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation
BK viremia is a significant issue in renal transplantation, with male sex, older age, and maintenance steroids identified as key risk factors. The study found that BKV negatively impacts graft and patient survival, highlighting the need for a unified treatment approach.
Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy
This study found that high neutralizing antibody titers against the replicating strain reduce the risk of BK viremia, suggesting a role of neutralizing antibodies in managing BK viremia.
Antibodies against Endogenous Retroviruses Promote Lung Cancer Immunotherapy
Cancer derived antibodies have anti-tumour activity and promote response to lung cancer immunotherapy
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
In most cancer indications, B cells are associated with a favourable prognostic outcome.
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma
B cells are associated with a favourable cancer prognosis in lung cancer
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Tumour infiltrating B cells secrete antibodies that bind cancer cells and show functional anti-tumour activity in ovarian cancer.
Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy
B cells develop within tumours in tertiary lymphoid structures.
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
The DROPZYLLA® platform was used in early 2020 to rapidly generate SARS-CoV-2-specific antibodies from convalescent COVID-19 donors, yielding neutralizing antibodies within 3-6 weeks. One antibody, MTX-COVAB, showed strong efficacy against all known variants at that time and went into clinical development.
Antibody repertories of tumor-infiltrating B cells
This poster, presented 2023 at CICON, details the diverse antibody repertoires of tumor-infiltrating B cells, highlighting their potential for anti-tumor activity and the use of the Dropzylla platform for comprehensive analysis and biobanking.
Discovery of superior functional antibodies from comprehensive recombinant antibody repertoires
This poster, presented 2022 at PEGS Europe, describes the discovery of superior functional antibodies using Dropzylla, a microfluidic-based single-cell analysis platform, highlighting its comprehensive antibody repertoire coverage and high-throughput screening capabilities for therapeutic applications.
Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research
This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
The DROPZYLLA® platform was used in early 2020 to rapidly generate SARS-CoV-2-specific antibodies from convalescent COVID-19 donors, yielding neutralizing antibodies within 3-6 weeks. One antibody, MTX-COVAB, showed strong efficacy against all known variants at that time and went into clinical development.
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
BKV-nephropathy remains a major cause of premature kidney allograft failure, necessitating proactive screening, monitoring, and timely immunosuppression reduction. The updated Second International Consensus Guidelines review significant advances and provide updated recommendations, emphasizing the need for further research and randomized clinical trials.
Antibody repertories of tumor-infiltrating B cells
This poster, presented 2023 at CICON, details the diverse antibody repertoires of tumor-infiltrating B cells, highlighting their potential for anti-tumor activity and the use of the Dropzylla platform for comprehensive analysis and biobanking.
Antibodies against Endogenous Retroviruses Promote Lung Cancer Immunotherapy
Cancer derived antibodies have anti-tumour activity and promote response to lung cancer immunotherapy
Discovery of superior functional antibodies from comprehensive recombinant antibody repertoires
This poster, presented 2022 at PEGS Europe, describes the discovery of superior functional antibodies using Dropzylla, a microfluidic-based single-cell analysis platform, highlighting its comprehensive antibody repertoire coverage and high-throughput screening capabilities for therapeutic applications.
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
In most cancer indications, B cells are associated with a favourable prognostic outcome.
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma
B cells are associated with a favourable cancer prognosis in lung cancer
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Tumour infiltrating B cells secrete antibodies that bind cancer cells and show functional anti-tumour activity in ovarian cancer.
Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research
This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
BKV-nephropathy remains a major cause of premature kidney allograft failure, necessitating proactive screening, monitoring, and timely immunosuppression reduction. The updated Second International Consensus Guidelines review significant advances and provide updated recommendations, emphasizing the need for further research and randomized clinical trials.
Advancing Patient-Centered Research: Enabling the Patient Voice to Be Heard
The article discusses the importance of incorporating the patient voice in patient-centered research, particularly in the context of kidney diseases, to improve healthcare outcomes and ensure that patient perspectives and needs are adequately addressed.
BK Virus Infection and BK-Virus-Associated Nephropathy in Renal Transplant Recipients
BK polyomavirus (BKV) is highly infective, often causing asymptomatic infections in childhood and remaining latent in kidney cells. In renal transplant recipients, BKV can reactivate, leading to nephropathy and significant graft loss, with current treatments focusing on reducing immunosuppression and emphasizing the importance of early diagnosis and surveillance for better outcomes.
The economic burden of kidney graft failure in the United States
The economic burden of kidney graft failure is significant. Reducing graft failure would improve quality of life, extend patient survival, and result in reduced health care spending.
Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation
BK viremia is a significant issue in renal transplantation, with male sex, older age, and maintenance steroids identified as key risk factors. The study found that BKV negatively impacts graft and patient survival, highlighting the need for a unified treatment approach.
Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy
This study found that high neutralizing antibody titers against the replicating strain reduce the risk of BK viremia, suggesting a role of neutralizing antibodies in managing BK viremia.
Antibodies against Endogenous Retroviruses Promote Lung Cancer Immunotherapy
Cancer derived antibodies have anti-tumour activity and promote response to lung cancer immunotherapy
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
In most cancer indications, B cells are associated with a favourable prognostic outcome.
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma
B cells are associated with a favourable cancer prognosis in lung cancer
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Tumour infiltrating B cells secrete antibodies that bind cancer cells and show functional anti-tumour activity in ovarian cancer.
Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy
B cells develop within tumours in tertiary lymphoid structures.
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
The DROPZYLLA® platform was used in early 2020 to rapidly generate SARS-CoV-2-specific antibodies from convalescent COVID-19 donors, yielding neutralizing antibodies within 3-6 weeks. One antibody, MTX-COVAB, showed strong efficacy against all known variants at that time and went into clinical development.
Antibody repertories of tumor-infiltrating B cells
This poster, presented 2023 at CICON, details the diverse antibody repertoires of tumor-infiltrating B cells, highlighting their potential for anti-tumor activity and the use of the Dropzylla platform for comprehensive analysis and biobanking.
Discovery of superior functional antibodies from comprehensive recombinant antibody repertoires
This poster, presented 2022 at PEGS Europe, describes the discovery of superior functional antibodies using Dropzylla, a microfluidic-based single-cell analysis platform, highlighting its comprehensive antibody repertoire coverage and high-throughput screening capabilities for therapeutic applications.
